https://www.selleckchem.com/pr....oducts/BI6727-Volase
The safety profiles were similar in both the treatment groups with mild-moderate adverse effects. The PK characteristics and immunogenicity exhibited by HL02 were similar to that of the reference product, US-trastuzumab. The safety profiles were similar in both the treatment groups with mild-moderate adverse effects.While sarcoma immunology has advanced with regard to basic, and even some applied topics, this disease has not been subject to more recent immunogenomics approaches. Thus, we assessed the immune receptor recombinat
Aimer
Commentaire
Partagez
